Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression
- Author
- ORLOWSKI, Robert Z; NAGLER, Arnon; SPICKA, Ivan; SUTHERLAND, Heather J; SUVOROV, Alexander N; ZHUANG, Sen H; PAREKH, Trilok; LIANG XIU; ZHILONG YUAN; RACKOFF, Wayne; HAROUSSEAU, Jean-Luc; SONNEVELD, Pieter; BLADE, Joan; HAJEK, Roman; SPENCER, Andrew; SAN MIGUEL, Jesus; ROBAK, Tadeusz; DMOSZYNSKA, Anna; HORVATH, Noemi
[1] University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
[2] Chaim Sheba Medical Center, Tel Hashomer, Israel
[3] Erasmus MC, Rotterdam, Netherlands
[4] Hospital Clinic I Provincial, Barcelona, Spain
[5] Interni Hematoonkologická klinika Fakultní Brno, Brno, Czech Republic
[6] General Faculty Hospital, Prague, Czech Republic
[7] Alfred Hospital, Melbourne, Australia
[8] Institute of Medicine and Veterinary Science, Adelaide, Australia
[9] Hospital Universitario de Salamanca, Centro de Investigación del Cáncer-IBMCC (CSIC-USAL), Spain
[10] Medical University of Lodz, Lodz, Poland
[11] Medical University of Lublin, Lublin, Poland
[12] University of British Columbia, Vancouver, Canada
[13] First Republican Clinical Hospital of Udmurtia, Izhevsk, Russian Federation
[14] Johnson & Johnson Pharmaceutical Research & Development LLC, Raritan, NJ, United States
[15] University Hospital Hotel-Dieu, Nantes, France - Source
Journal of clinical oncology. 2007, Vol 25, Num 25, pp 3892-3901, 10 p ; ref : 26 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- Lippincott Williams & Wilkins, Baltimore, MD
- Publication country
- United States
- Document type
- Article
- Language
- Russian
- Keyword (fr)
- Anticancéreux Bortézomib Cancérologie Doxorubicine Essai clinique phase III Etude comparative Forme pégylée Liposome Myélome Randomisation Récidive Résistance traitement Traitement associé Acide boronique Inhibiteur de la topoisomérase II Inhibiteur du protéasome Analogue Anthracyclines DNA topoisomerase (ATP-hydrolysing) Dipeptide Enzyme Hémopathie maligne Immunoglobulinopathie Immunopathologie Inhibiteur enzyme Isomerases Lymphoprolifératif syndrome
- Keyword (en)
- Antineoplastic agent Bortezomib Cancerology Doxorubicin Phase III trial Comparative study Pegylated form Liposome Myeloma Randomization Relapse Treatment resistance Combined treatment Analog Anthracyclins DNA topoisomerase (ATP-hydrolysing) Dipeptides Enzyme Malignant hemopathy Immunoglobulinopathy Immunopathology Enzyme inhibitor Isomerases Lymphoproliferative syndrome
- Keyword (es)
- Anticanceroso Bortezomib Cancerología Doxorubicina Ensayo clínico fase III Estudio comparativo Forma pegilada Liposoma Mieloma Aleatorización Recaida Resistencia tratamiento Tratamiento asociado Análogo Antraciclinas DNA topoisomerase (ATP-hydrolysing) Dipéptido Enzima Hemopatía maligna Inmunoglobulinopatía Inmunopatología Inhibidor enzima Isomerases Linfoproliferativo síndrome
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B06 Immunopathology / 002B06D Immunodeficiencies. Immunoglobulinopathies / 002B06D02 Immunoglobulinopathies
- Discipline
- Immunopathology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 19075409
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2006.10.5460 
https://dx.doi.org/10.1200/JCO.2006.10.5460
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5460\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:202:\"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"25\";s:8:\"\u0000*\u0000spage\";s:4:\"3892\";s:8:\"\u0000*\u0000epage\";s:4:\"3901\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ORLOWSKI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Robert Z\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:13:\"NAGLER, Arnon\";i:1;s:12:\"SPICKA, Ivan\";i:2;s:21:\"SUTHERLAND, Heather J\";i:3;s:20:\"SUVOROV, Alexander N\";i:4;s:13:\"ZHUANG, Sen H\";i:5;s:14:\"PAREKH, Trilok\";i:6;s:9:\"LIANG XIU\";i:7;s:12:\"ZHILONG YUAN\";i:8;s:14:\"RACKOFF, Wayne\";i:9;s:20:\"HAROUSSEAU, Jean-Luc\";i:10;s:17:\"SONNEVELD, Pieter\";i:11;s:11:\"BLADE, Joan\";i:12;s:12:\"HAJEK, Roman\";i:13;s:15:\"SPENCER, Andrew\";i:14;s:17:\"SAN MIGUEL, Jesus\";i:15;s:14:\"ROBAK, Tadeusz\";i:16;s:16:\"DMOSZYNSKA, Anna\";i:17;s:14:\"HORVATH, Noemi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:202:\"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5460\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:202:\"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"25\";s:8:\"\u0000*\u0000spage\";s:4:\"3892\";s:8:\"\u0000*\u0000epage\";s:4:\"3901\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ORLOWSKI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Robert Z\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:13:\"NAGLER, Arnon\";i:1;s:12:\"SPICKA, Ivan\";i:2;s:21:\"SUTHERLAND, Heather J\";i:3;s:20:\"SUVOROV, Alexander N\";i:4;s:13:\"ZHUANG, Sen H\";i:5;s:14:\"PAREKH, Trilok\";i:6;s:9:\"LIANG XIU\";i:7;s:12:\"ZHILONG YUAN\";i:8;s:14:\"RACKOFF, Wayne\";i:9;s:20:\"HAROUSSEAU, Jean-Luc\";i:10;s:17:\"SONNEVELD, Pieter\";i:11;s:11:\"BLADE, Joan\";i:12;s:12:\"HAJEK, Roman\";i:13;s:15:\"SPENCER, Andrew\";i:14;s:17:\"SAN MIGUEL, Jesus\";i:15;s:14:\"ROBAK, Tadeusz\";i:16;s:16:\"DMOSZYNSKA, Anna\";i:17;s:14:\"HORVATH, Noemi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:202:\"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5460\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5460\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:202:\"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"25\";s:8:\"\u0000*\u0000spage\";s:4:\"3892\";s:8:\"\u0000*\u0000epage\";s:4:\"3901\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ORLOWSKI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Robert Z\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:13:\"NAGLER, Arnon\";i:1;s:12:\"SPICKA, Ivan\";i:2;s:21:\"SUTHERLAND, Heather J\";i:3;s:20:\"SUVOROV, Alexander N\";i:4;s:13:\"ZHUANG, Sen H\";i:5;s:14:\"PAREKH, Trilok\";i:6;s:9:\"LIANG XIU\";i:7;s:12:\"ZHILONG YUAN\";i:8;s:14:\"RACKOFF, Wayne\";i:9;s:20:\"HAROUSSEAU, Jean-Luc\";i:10;s:17:\"SONNEVELD, Pieter\";i:11;s:11:\"BLADE, Joan\";i:12;s:12:\"HAJEK, Roman\";i:13;s:15:\"SPENCER, Andrew\";i:14;s:17:\"SAN MIGUEL, Jesus\";i:15;s:14:\"ROBAK, Tadeusz\";i:16;s:16:\"DMOSZYNSKA, Anna\";i:17;s:14:\"HORVATH, Noemi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:202:\"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5460\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:202:\"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"25\";s:8:\"\u0000*\u0000spage\";s:4:\"3892\";s:8:\"\u0000*\u0000epage\";s:4:\"3901\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ORLOWSKI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Robert Z\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:13:\"NAGLER, Arnon\";i:1;s:12:\"SPICKA, Ivan\";i:2;s:21:\"SUTHERLAND, Heather J\";i:3;s:20:\"SUVOROV, Alexander N\";i:4;s:13:\"ZHUANG, Sen H\";i:5;s:14:\"PAREKH, Trilok\";i:6;s:9:\"LIANG XIU\";i:7;s:12:\"ZHILONG YUAN\";i:8;s:14:\"RACKOFF, Wayne\";i:9;s:20:\"HAROUSSEAU, Jean-Luc\";i:10;s:17:\"SONNEVELD, Pieter\";i:11;s:11:\"BLADE, Joan\";i:12;s:12:\"HAJEK, Roman\";i:13;s:15:\"SPENCER, Andrew\";i:14;s:17:\"SAN MIGUEL, Jesus\";i:15;s:14:\"ROBAK, Tadeusz\";i:16;s:16:\"DMOSZYNSKA, Anna\";i:17;s:14:\"HORVATH, Noemi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:202:\"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5460\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:202:\"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"25\";s:8:\"\u0000*\u0000spage\";s:4:\"3892\";s:8:\"\u0000*\u0000epage\";s:4:\"3901\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ORLOWSKI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Robert Z\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:18:{i:0;s:13:\"NAGLER, Arnon\";i:1;s:12:\"SPICKA, Ivan\";i:2;s:21:\"SUTHERLAND, Heather J\";i:3;s:20:\"SUVOROV, Alexander N\";i:4;s:13:\"ZHUANG, Sen H\";i:5;s:14:\"PAREKH, Trilok\";i:6;s:9:\"LIANG XIU\";i:7;s:12:\"ZHILONG YUAN\";i:8;s:14:\"RACKOFF, Wayne\";i:9;s:20:\"HAROUSSEAU, Jean-Luc\";i:10;s:17:\"SONNEVELD, Pieter\";i:11;s:11:\"BLADE, Joan\";i:12;s:12:\"HAJEK, Roman\";i:13;s:15:\"SPENCER, Andrew\";i:14;s:17:\"SAN MIGUEL, Jesus\";i:15;s:14:\"ROBAK, Tadeusz\";i:16;s:16:\"DMOSZYNSKA, Anna\";i:17;s:14:\"HORVATH, Noemi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:202:\"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progression\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
